Induction of analgesia using atorvastatin in experimental diabetic neuropathy through NMDA receptor and inflammatory cytokines inhibition

Background: Diabetic neuropathy is a complication of diabetes causing damage to the nerves. Objectives: Considering the neuroprotective anti-inflammatory antioxidant characteristics of statins, the current study aimed at determining the effects of atorvastatin on diabetic neuropathy through assessing the involvement of the N-methyl-D-aspartic acid (NMDA) receptor, factors of oxidative stress, and inflammatory cytokines in rats with diabetes. Methods: Male rats were randomly assigned into six groups of saline- and atorvastatin-treated controls, streptozotocin-induced diabetic animals treated with vehicle, diabetic animals treated with morphine (5 mg/kg), and rats treated with atorvastatin (10 mg/kg/day for 10 weeks) alone or in combination with NMDA receptor agonist. The hot plate and formalin tests were carried out on the rats. Moreover, malondialdehyde level, catalase and superoxide dismutase activities, and levels of interleukin 1 beta (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF-α) in the dorsal root ganglia (DRG) of the animals were measured. Finally, the expression of the NMDA receptor in DRG was investigated in the current study. Results: According to the findings, diabetes resulted in analgesia in all the tests, and pretreatment with atorvastatin exacerbated diabetes-induced analgesic effects in the hot plate test and early phase of the formalin test (P≤0.01 and P≤0.05 in comparison to those reported for the diabetic vehicle-treated group, respectively). The injection of NMDA could reverse the atorvastatin-induced analgesia in the hot plate test (P≤0.05). Diabetes caused an increase in the levels of IL-1β, IL-6, and TNF-α in DRG in comparison to those reported for the control group (P≤0.05). Furthermore, the pretreatment of rats using atorvastatin could significantly reverse the increase in TNF-α level (P≤0.05). Conclusion: Atorvastatin showed analgesic properties, which might be acting through NMDA receptors and reduction of inflammatory cytokines.

[1]  P. Magnusson,et al.  Statins and Neuropathic Pain: A Narrative Review , 2020, Pain and Therapy.

[2]  T. Kamarul,et al.  Protective effects of atorvastatin on high glucose-induced oxidative stress and mitochondrial apoptotic signaling pathways in cultured chondrocytes , 2019, Journal of Physiology and Biochemistry.

[3]  M. Tymianski,et al.  Targeting NMDA receptors in stroke: new hope in neuroprotection , 2018, Molecular Brain.

[4]  A. Gulati,et al.  A Systematic Review of NMDA Receptor Antagonists for Treatment of Neuropathic Pain in Clinical Practice , 2017, The Clinical journal of pain.

[5]  C. Tasca,et al.  In vitro 6-hydroxydopamine-induced toxicity in striatal, cerebrocortical and hippocampal slices is attenuated by atorvastatin and MK-801. , 2016, Toxicology in vitro : an international journal published in association with BIBRA.

[6]  B. Albensi,et al.  Neuronal Gene Targets of NF-κB and Their Dysregulation in Alzheimer's Disease , 2016, Front. Mol. Neurosci..

[7]  A. Rodrigues,et al.  Involvement of PI3K/Akt/GSK-3β and mTOR in the antidepressant-like effect of atorvastatin in mice. , 2016, Journal of psychiatric research.

[8]  A. Dehpour,et al.  Studying neuroprotective effect of Atorvastatin as a small molecule drug on high glucose-induced neurotoxicity in undifferentiated PC12 cells: role of NADPH oxidase , 2016, Metabolic Brain Disease.

[9]  Hassane S. Mchaourab,et al.  Mechanism of NMDA Receptor Inhibition and Activation , 2016, Cell.

[10]  Zhiyong Ji,et al.  Atorvastatin attenuates inflammation and oxidative stress induced by ischemia/reperfusion in rat heart via the Nrf2 transcription factor. , 2015, International journal of clinical and experimental medicine.

[11]  N. Sattar,et al.  The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. , 2014, Atherosclerosis. Supplements.

[12]  N. N. Pathak,et al.  Atorvastatin attenuates neuropathic pain in rat neuropathy model by down-regulating oxidative damage at peripheral, spinal and supraspinal levels , 2014, Neurochemistry International.

[13]  J. Gagliardino,et al.  Diabetes in Argentina: cost and management of diabetes and its complications and challenges for health policy , 2013, Globalization and Health.

[14]  A. C. Lo,et al.  Animal Models of Diabetic Retinopathy: Summary and Comparison , 2013, Journal of diabetes research.

[15]  M. Abdollahi,et al.  Diabetic Neuropathy and Oxidative Stress: Therapeutic Perspectives , 2013, Oxidative medicine and cellular longevity.

[16]  H. Pan,et al.  Targeting N-methyl-D-aspartate receptors for treatment of neuropathic pain , 2011, Expert review of clinical pharmacology.

[17]  A. Dahan,et al.  NMDA receptor antagonists for the treatment of neuropathic pain. , 2010, Pain medicine.

[18]  B. Tayade,et al.  Spirometry and diffusion studies in patients with type-2 diabetes mellitus and their association with microvascular complications. , 2010, The Indian journal of chest diseases & allied sciences.

[19]  R. Freeman,et al.  Diabetic Neuropathy , 2010, Diabetes Care.

[20]  P. Dandawate,et al.  Antioxidant, antinociceptive and anti-inflammatory activities of atorvastatin and rosuvastatin in various experimental models , 2010, Inflammopharmacology.

[21]  A. Vinik,et al.  Diabetic neuropathy in older adults. , 2008, Clinics in geriatric medicine.

[22]  Soroku Yagihashi,et al.  Pathology and pathogenetic mechanisms of diabetic neuropathy: correlation with clinical signs and symptoms. , 2007, Diabetes research and clinical practice.

[23]  M. Teixeira,et al.  Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. , 2005, European journal of pharmacology.

[24]  M. Endres,et al.  Neuroprotective effects of atorvastatin against glutamate‐induced excitotoxicity in primary cortical neurones , 2005, Journal of neurochemistry.

[25]  O. Pachinger,et al.  HMG-CoA Reductase Inhibitors Regulate Inflammatory Transcription Factors in Human Endothelial and Vascular Smooth Muscle Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[26]  Yongsoo Park Chapter 1 – Oxidative Stress and Diabetic Neuropathy , 2014 .

[27]  A. A. El-Asrar Role of Inflammation in the Pathogenesis of Diabetic Retinopathy , 2012, Middle East African journal of ophthalmology.

[28]  T. Sano,et al.  [Diabetic retinopathy]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.